

Listing of the Claims:

1-81. (Canceled)

82. (Previously presented) A method for treating mood disorders or anxiety disorders comprising administering to a patient pipamperone, or a pharmaceutically acceptable salt thereof, in a dose ranging between 5 and 15 mg per day of the active ingredient, and administering said pipamperone simultaneously with, separate from or sequential to a second compound, to augment the therapeutic effect of said second compound or to provide a faster onset of the therapeutic effect of said second compound, wherein said second compound is selected from the group consisting of: selective serotonin, nor-adrenaline and dopamine re-uptake inhibitors (SNDRI), selective serotonin and nor-adrenaline re-uptake inhibitors (SNRI) and selective serotonin re-uptake inhibitors (SSRI).

83. (Previously presented) The method according to claim 82, wherein said pipamperone is administered daily at least one day before administering said second compound.

84. (Previously presented) The method according to claim 82, wherein said second compound is a selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound.

85. (Previously presented) The method according to claim 84, wherein said selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound is selected from the group consisting of NS 2330, McN 5652, DOV 216,303

and DOV 21,947, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.

86. (Previously presented) A pharmaceutical composition comprising (a) pipamperone, and (b) a selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound, as a combined preparation for simultaneous, separate or sequential use for treating mood disorders or anxiety disorders, wherein said pipamperone is provided in a unitary dose of between 5 and 15 mg of the active ingredient.

87. (Previously presented) The pharmaceutical composition according to claim 86, wherein said selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound is selected from the group consisting of NS 2330, McN 5652, DOV 216,303 and DOV 21,947, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.

88. (Previously presented) The method according to claim 82, wherein said second compound is a selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound.

89. (Previously presented) The method according to claim 88, wherein said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is selected from the group consisting of venlafaxine, tomoxetine, tandamine, talsupram, talopram, nefazodone, milnacipran, LY 113.821, duloxetine, desvenlafaxine and amoxapine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.

90. (Previously presented) The method according to claim 89, wherein said venlafaxine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, is administered in a daily dose ranging between 75 and 300 mg of the active ingredient.

91. (Previously presented) The method according to claim 89, wherein said tomoxetine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, is administered in a daily dose ranging between 0.475 and 3.8 mg/kg of the active ingredient.

92. (Previously presented) The method according to claim 89, wherein said milnacipran, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, is administered in a daily dose ranging between 50 and 200 mg of the active ingredient.

93. (Previously presented) The method according to claim 89, wherein said duloxetine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, is administered in a daily dose ranging between 40 and 60 mg of the active ingredient.

94. (Previously presented) A pharmaceutical composition comprising (a) pipamperone and (b) a selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound as a combined preparation for simultaneous, separate or sequential use for treating mood disorders or anxiety disorders, wherein said pipamperone is provided in a unitary dose of between 5 and 15 mg of the active ingredient.

95. (Previously presented) The pharmaceutical composition according to claim 94, wherein said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is selected from the group consisting of venlafaxine, tomoxetine, tandamine, talsupram, talopram, nefazodone, milnacipran, LY 113.821, duloxetine, desvenlafaxine and amoxapine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof,

96. (Previously presented) The pharmaceutical composition according to claim 95, wherein said venlafaxine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, provided in a unitary dose of between 75 and 300 mg of the active ingredient.

97. (Previously presented) The pharmaceutical composition according to claim 95, wherein said tomoxetine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 38 and 304 mg of the active ingredient.

98. (Previously presented) The pharmaceutical composition according to claim 95, wherein said milnacipran, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 50 and 200 mg of the active ingredient.

99. (Previously presented) The pharmaceutical composition according to claim 95, wherein said duloxetine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 40 and 60 mg of the active ingredient.

100. (Previously presented) The method according to claim 82, wherein said second compound is a selective serotonin re-uptake inhibitor (SSRI) compound.

101. (Previously presented) The method according to claim 100, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is selected from the group consisting of YM 992, VPI-013 (OPC-14523), sertraline, paroxetine, LY 214.281, LU AA 21-004, Lu 35-138, litoxetine, ifoxetine, fluvoxamine (controlled release formulation), fluvoxamine, fluoxetine, femoxetine, escitalopram, EMD 68843, cyanodothepine, citalopram, venlafaxine, milnacipran, duloxetine, ademethionine (preferably s-adenosylmethionine) and cericlamine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.

102. (Previously presented) The method according to claim 101, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is fluvoxamine (controlled release formulation), or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, is administered in a daily dose ranging between 100 and 300 mg of the active ingredient.

103. (Previously presented) The method according to claim 101, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is escitalopram, or a pro-drug or an active metabolite thereof, and is administered in a daily dose ranging between 10 and 20 mg of the active ingredient.

104. (Previously presented) The method according to claim 101, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is citalopram, or a pro-drug or

an active metabolite thereof, and is administered in a daily dose ranging between 10 and 40 mg of the active ingredient.

105. (Previously presented) A pharmaceutical composition comprising (a) pipamperone and (b) a selective serotonin re-uptake inhibitor (SSRI) compound as a combined preparation for simultaneous, separate or sequential use for treating mood disorders or anxiety disorders, wherein said pipamperone is provided in a unitary dose of between 5 and 15 mg of the active ingredient.

106. (Previously presented) The pharmaceutical composition according to claim 105, wherein said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is selected from the group consisting of YM 992, VPI-013 (OPC-14523), sertraline, paroxetine, LY 214.281, LU AA 21-004, Lu 35-138, litoxetine, ifoxetine, fluvoxamine (controlled release formulation), fluvoxamine, fluoxetine, femoxetine, escitalopram, EMD 68843, cyanodothepine, citalopram, venlafaxine, milnacipran, duloxetine, cericlamine and ademethionine (preferably s-adenosylmethionine), or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.

107. (Previously presented) The pharmaceutical composition according to claim 106, wherein said fluvoxamine (controlled release formulation), or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 100 and 300 mg of the active ingredient.

108. (Previously presented) The pharmaceutical composition according to claim 106, wherein said escitalopram, or a pro-drug or an active metabolite thereof, or a

Applicant: Erik Buntinx
Serial No.: 10/580,962
Filed: May 31, 2006
Page 8 of 12

pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 10 and 20 mg of the active ingredient.

109. (Previously presented) The pharmaceutical composition according to claim 106, wherein said citalopram, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 10 and 40 mg of the active ingredient.